Clinical outcomes of patients with recurrent drug induced liver injury

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042056

Enrollment

Unknown

Registered

2021-01-13

Start date

2021-01-10

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced liver injury

Interventions

progression of AIH group vs without AIH group:Nil

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Inpatients with acute drug-induced liver injury; (2) Recurrent drug-induced liver injury; (3) Those who voluntarily participate in the study and sign the informed consent; (4) Aged 16 to 65 years.

Exclusion criteria

Exclusion criteria: (1) patients with acute liver failure, subacute liver failure, chronic liver failure; (2) have other basic liver diseases except fatty liver; (3) Pregnant or lactating women; (4) patients with primary liver cancer; (5) patients with other serious systemic diseases and mental illness; (6) HIV-positive people; Patients with hepatitis A, C, D, E virus, cytomegalovirus, Epstein-Barr virus; (7) Poor compliance can not guarantee the completion of researchers according to this study program.

Design outcomes

Primary

Measure	Time frame
Hematological examination (blood routine, prothrombin time, liver function, Shengong, serum markers of hepatitis B, etc.);Abdominal B ultrasound;	—

Countries

China

Contacts

Public ContactTingting He

The Fifth Medical Center, PLA General Hospital

1295525024@qq.com+86 18811198351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026